SEARCH

SEARCH BY CITATION

References

  • 1
    Funk ML, Rosenberg DM, Lok ASF. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 2002; 9: 5261.
  • 2
    Hadziyannis SJ. Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hepat Rev 1995; 1: 736.
  • 3
    Brunetto MR, Olivieri F, Rocca G, et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibodies to hepatitis B e antigen. Hepatology 1989; 10: 198202.
  • 4
    Keeffe EB, Dieterich DT, Han SHB, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004; 2: 87106.
  • 5
    Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999; 29: 88996.
  • 6
    Hadziyannis SJ, Papatheodoridis GV, Dimou E, et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32: 84751.
  • 7
    Santantonio T, Mazzola M, Iacovazzi T, et al. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000; 32: 3006.
  • 8
    Leung NWY, Lai C-L, Chang T-T, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33: 152732.
  • 9
    Marcellin P, Chang T-T, Lim SG, et al. Adefovir dipivoxil for the treatment of patients hepatitis B e antigen positive chronic hepatitis B. N Engl J Med 2003; 348: 80816.
  • 10
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 8007.
  • 11
    Di Marco V, Marzano A, Lampertico P, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004; 40: 88391.
  • 12
    Liaw YF, Sung JJY, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advance liver disease. N Engl J Med 2004; 351: 152131.
  • 13
    Peters MG, Hann HW, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91101.
  • 14
    Yuen MF, Lai CL. Adefovir dipivoxil in chronic hepatitis B infection. Expert Opin Pharmacother 2004; 5: 23617.
  • 15
    Gaia S, Marzano A, Smedile A, et al. Four years treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B. Aliment Pharmacol Ther 2004; 20: 2818.
  • 16
    Hadziyannis S, Tassopooulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352: 267381.
  • 17
    Hadziyannis S, Tassopoulos N, Chang TT, et al. Adefovir dipivoxil (ADV) demonstrates sustained efficacy in HBeAg chronic hepatitis B (CHB) patients. J Hepatol 2005; 42 (Suppl. 2): 178.
  • 18
    Papatheodoridis GV, Dimou E, Dimakopoulos K, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005; 42: 1219.
  • 19
    Vassiliadis T, Nikolaidis N, Giouleme O, et al. Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine resistant hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther 2005; 21: 5317.
  • 20
    Kanwal F, Gralnek IA, Martin P, et al. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med 2005; 142: 82131.
  • 21
    Evans C. The use of consensus methods and expert panels in pharmacoeconomic studies. Pharmacoeconomics 1997; 12: 1219.
  • 22
    Lai CL, Dienstang J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 68796.
  • 23
    Yang H, Westland CH, William E. Complete genotypic and phenotypic analyses of HBV mutations identified in HBeAg-negative chronic hepatitis B patients receiving 96 weeks of adefovir dipivoxil. Hepatology 2003; 38 (Suppl. 1): 705A.
  • 24
    Drummond MF, O'Brien B, Stoddart GL, et al. Basic types of economic evaluation. Critical assessment of economic evaluation. In: Drummond, MF, O'Brien, B, Stoddart, GL, Torrance, G, eds. Methods for the Economic Evaluation of Health Care Programmes, 2nd edn. Oxford, UK: Oxford University Press, 1997: 651.
  • 25
    Casado MA. Análisis parciales de evaluación económica de medicamentos: descripción de costes, estudios de coste de la enfermedad, análisis coste-consecuencia, análisis de costes. Análisis de minimización de costes. In: Domínguez-Gil, A, Soto, J, eds. Farmacoeconomía e investigación de resultados en la salud: principios y práctica, 2a edn. Madrid: Real Academia Nacional de Farmacia, 2001: 173208.
  • 26
    Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004; 39: 85761.
  • 27
    Crowley S, Tognarini D, Desmod P, et al. Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data. J Gastroenterol Hepatol 2002; 17: 15364.
  • 28
    Buti M, Casado MA, Fosbrook L, et al. Coste-efectividad del tratamiento de la hepatitis crónica C con interferon alfa. Gastroenterol Hepatol 1998; 21: 1618.
  • 29
    Soto J, Sacristán JA, Galende I. Estudios naturalísticos para valorar la efectividad de los medicamentos tras su comercialización: porqué, cuándo y cómo? Aten Primaria 1998; 22: 1825.
  • 30
    Dusheiko GM, Roberts J. Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal. Hepatology 1995; 22: 186373.
  • 31
    Orlewska E. The cost-effectiveness of alternative therapeutic strategies for the management of chronic hepatitis B in Poland. Value Health 2002; 5: 40421.
  • 32
    Aggarwal R, Ghoshal UC, Naik SR. Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model. J Hepatol 2003; 38: 21522.